Day 2 :
Keynote Forum
Hiltrud Brauch
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Germany
Keynote: Endocrine treatment of breast cancer: Current concepts to predict and prevent relapse
Biography:
Hiltrud Brauch has completed her PhD at the University of Heidelberg, Germany, and Postdoctoral studies as a Fogarty International Visiting Fellow at the National Institutes of Health (NIH), National Cancer Institute (NCI) Frederick, Maryland, USA. She is the Deputy Director of Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology in Stuttgart, a non-profit private research institute of the Robert Bosch Foundation. She has published more than 250 papers in reputed journals and has been serving as an Editorial Board Member of pharmacogenetics and genomics as well as pharmacogenomics and personalized medicine.
Abstract:
Standard-of-care in endocrine treatment is the blockade of estrogen signaling via long-term estrogen deprivation. Tamoxifen, a selective ER modulator blocks 17ß-estradiol binding to stop tumor growth, and aromatase inhibitors (AI) block the aromatase enzyme to prevent conversion of androgens to estrogens. Despite their effectiveness one third of the patients develop recurrences leading to disease progression and death. Tamoxifen failure is attributed to a lack of bioactivation towards its active metabolite endoxifen that is mainly mediated by the polymorphic CYP2D6 enzyme for which distinct genetically determined functional variants are present in the general population. Inter-individual differences in CYP2D6 enzyme activities are grouped into the phenotypes ultra-rapid (UM), extensive (EM), intermediate (IM) and poor (PM) metabolizers. EM patients have high levels of endoxifen and are likely to benefit whereas PM patients have low endoxifen levels and a significant risk to relapse. Therefore, CYP2D6 polymorphism and plasma endoxifen levels may serve as tamoxifen outcome predictors however findings from others do not support this view. I will discuss the controversy and suggest a way forward towards the improvement of tamoxifen outcome. With regards to AI treatment, long-term estrogen deprivation leads to the reconfiguration of survival signaling in that reconfigured tumor cells eventually become sensitive towards estrogen, a mechanism known as E2-inducible apoptosis. While this is being explored in clinical trials I will show that distinct microRNA patterns characterize AI resistance and discuss their potential as biomarkers to identify patients at risk for relapse and those susceptible to E2-inducible apoptosis towards the prevention of relapse.
Keynote Forum
Lloyd Jenkins
Budwig Center, Spain
Keynote: Naturopathic doctor in complementary natural treatment and prevention of cancer
Time : 10:00-10:30
Biography:
Lloyd Jenkins completed training and diploma in advanced TESOL Methodology at Canadian Institute of English and travelled extensively to promote language courses. He completed a diploma in Natural Medicine in 1997 and Doctorate in Natural Health Sciences in 2003 at Universidad International del Ecuador (UIDE). He holds a Bachelor of Education degree at Warnborough University of England and Doctorate in Natural Health Sciences at St. Petersburg University, Russia. He is a certified Therapist in Therapeutic Massage, EFT- (Emotional Freedom Technique) of California. He has also studied Naturopathy, Orthomolecular Medicine, pH Acid/Alkaline Balancing, Hyperthermia/Fever Therapy, Detoxification Methodology, Lymphatic Drainage, Sciatic & Nerve Restoration, Posture Correction and Interpersonal Human Relations.
Abstract:
The Budwig Center approach is based on the research and studies of the famous German Doctor, Dr. Johanna Budwig using a totally natural treatment protocol. She was a State Expert for Chemical Research on Drugs and Fats at the Dr. Kaufmann's facility in Munster, Germany. We are all aware of how fats clog up our veins and arteries and are the leading cause of heart attacks, but these very dangerous fats and oils are also affecting the overall health of our minds and bodies at the cellular level. Dr. Budwig discovered that when unsaturated fats have been chemically treated, their unsaturated qualities are destroyed and the field of electrons removed. Her most famous discovery was the use of a combination of flaxseed oil combined with Quark or Cottage cheese to restore the adequate electron activity. She also used mostly herbal, homeopathic, essential oils, sunbathing, oil massages and enemas, as well as her oil protein diet to treat and prevent cancer. In August 2000, Lloyd Jenkins visited the famous Dr. Johanna Budwig in her Cancer clinic in Stuttgart Germany. It was with deep interest that he listened to Dr. Budwig talk about her incredible health breakthrough of when she discovered the powerfully healing nature of essential fatty acids in treating cancer and all types of degenerative diseases. Lloyd received her permission to use her program in the BUDWIG CENTER Cancer clinic in Spain and has been helping people from all over the world since then to overcome cancer. What lead him into the career as a Naturopathic Doctor started really when at only 4 years of age his father died of a kidney failure and at 12 years of age his mother had to battle with cancer. Since then he has a deep fascination in understanding how the human body works and why people contracted certain diseases.